What is he best known for?
The fields of study he is best known for:
- Internal medicine
- Disease
- Surgery
His primary areas of study are Internal medicine, Crohn's disease, Surgery, Gastroenterology and Inflammatory bowel disease.
Remo Panaccione usually deals with Internal medicine and limits it to topics linked to Placebo and Randomized controlled trial and Maintenance therapy.
His Crohn's disease research integrates issues from Severity of illness, Incidence, Immunology and Chemotherapy.
His studies examine the connections between Surgery and genetics, as well as such issues in Vedolizumab, with regards to Dosing, Quality of life and Natalizumab.
His research in Gastroenterology intersects with topics in Crohn's Disease Activity Index, Azathioprine, Infliximab and C-reactive protein.
His Inflammatory bowel disease research is multidisciplinary, relying on both Biomarker, Physical therapy, Biopsy and Intensive care medicine.
His most cited work include:
- Increasing Incidence and Prevalence of the Inflammatory Bowel Diseases With Time, Based on Systematic Review (2933 citations)
- Adalimumab for maintenance of clinical response and remission in patients with Crohn's disease: the CHARM trial. (1681 citations)
- Human Anti–Tumor Necrosis Factor Monoclonal Antibody (Adalimumab) in Crohn’s Disease: the CLASSIC-I Trial (1331 citations)
What are the main themes of his work throughout his whole career to date?
His scientific interests lie mostly in Internal medicine, Crohn's disease, Ulcerative colitis, Gastroenterology and Inflammatory bowel disease.
Many of his research projects under Internal medicine are closely connected to In patient with In patient, tying the diverse disciplines of science together.
Remo Panaccione has researched Crohn's disease in several fields, including Ustekinumab, Adverse effect, Surgery and Clinical trial.
His Ulcerative colitis study incorporates themes from Tofacitinib, Randomized controlled trial, Colitis and MEDLINE.
His work carried out in the field of Gastroenterology brings together such families of science as Colonoscopy and Placebo.
His Inflammatory bowel disease study integrates concerns from other disciplines, such as Inflammation and Immunology.
He most often published in these fields:
- Internal medicine (59.48%)
- Crohn's disease (38.39%)
- Ulcerative colitis (32.93%)
What were the highlights of his more recent work (between 2018-2021)?
- Internal medicine (59.48%)
- Ulcerative colitis (32.93%)
- Crohn's disease (38.39%)
In recent papers he was focusing on the following fields of study:
Internal medicine, Ulcerative colitis, Crohn's disease, Gastroenterology and Inflammatory bowel disease are his primary areas of study.
His study in the field of Ustekinumab, Adalimumab, Disease and Vedolizumab also crosses realms of In patient.
His Ulcerative colitis study combines topics in areas such as Adverse effect, Tofacitinib, Chromoendoscopy and Clinical trial.
The various areas that he examines in his Crohn's disease study include Disease progression, Surgery, Lower risk, Immunology and Calprotectin.
As a part of the same scientific study, Remo Panaccione usually deals with the Gastroenterology, concentrating on Placebo and frequently concerns with Randomized controlled trial.
His Inflammatory bowel disease research includes themes of Colitis, Epidemiology, Incidence, Quality of life and Intensive care medicine.
Between 2018 and 2021, his most popular works were:
- Management of Patients With Crohn's Disease and Ulcerative Colitis During the Coronavirus Disease-2019 Pandemic: Results of an International Meeting. (94 citations)
- Past and Future Burden of Inflammatory Bowel Diseases Based on Modeling of Population-Based Data. (83 citations)
- Tofacitinib Induction Therapy Reduces Symptoms Within 3 Days for Patients With Ulcerative Colitis (64 citations)
In his most recent research, the most cited papers focused on:
- Internal medicine
- Disease
- Cancer
His main research concerns Internal medicine, Ulcerative colitis, Crohn's disease, Inflammatory bowel disease and Gastroenterology.
In most of his Internal medicine studies, his work intersects topics such as Placebo.
His studies deal with areas such as Tofacitinib, Rheumatoid arthritis, Clinical trial, Prospective cohort study and Severity of illness as well as Ulcerative colitis.
His work on Crohn's Disease Activity Index as part of his general Crohn's disease study is frequently connected to Long term data, thereby bridging the divide between different branches of science.
His studies in Inflammatory bowel disease integrate themes in fields like Colectomies, Colitis, Epidemiology, Incidence and Risk factor.
The study incorporates disciplines such as Post-hoc analysis, Randomization, Hazard ratio, Biomarker and Induction therapy in addition to Gastroenterology.
This overview was generated by a machine learning system which analysed the scientist’s
body of work. If you have any feedback, you can
contact us
here.
